Impact on Quality of Life With Pulmonary RehAbilitation After Pulmonary eMBOlism: RAMBO Study

Overview

Pulmonary Embolism (PE) is a common and serious disease. Indeed, the annual incidence is 1/1000 patients per year and the 3-month mortality is 10%, which is twice that of myocardial infarction. The treatment is based on anticoagulation for at least 3 months. However, after three or six months of anticoagulation, persistent dyspnea and impairment of quality of life are observed in at least 30% of cases. Several mechanisms explain dyspnea and impairment of quality of life after PE, such as residual pulmonary artery obstruction, exercise deconditioning, depressive syndrome or development of a cardio-respiratory pathology. Pulmonary rehabilitation (PR) has been shown to be effective on dyspnea and quality of life and is included in the therapeutic management of chronic respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD) or pulmonary fibrosis. Furthermore, PR is also used after a myocardial infarction. However, PR after PE is still not included in therapeutic management of PE while outpatient management is recommended for the majority of patients after an acute PE episode. Study hypothesis is that PR has the potential to improve quality of life and dyspnea perception in patients who have received anticoagulation for at least 3 months after PE and who present an impairment of quality of life and/or a persistent dyspnea. This study presents several innovative aspects. First, to our knowledge, This study is the first large randomized trial assessing PR at least 3 months after acute symptomatic PE. Only one small randomized trial on 18 patients evaluating the impact of PR after PE has been published; as PR was performed just after the acute phase of PE in this trial, the clinical status improvement observed in this study could not be explained by PR alone, but also by anticoagulation. In this study, the investigators will include 112 patients at least 3 months after PE in order to exclude the bias related to anticoagulation effect. Second, This study is the first large randomized trial. Third, this study is the first that have the potential to demonstrate efficacy and safety of delayed PR after PE in patients with impaired quality of life due to persistent residual dyspnea.

Interventions

• Other Pulmonary rehabilitation (PR)
  20 sessions of PR in respiratory rehabilitation centre will be performed over a period of 3 months

Primary outcome measures

• Quality of life - PEmbQoL score [Time frame: 3 months]

Secondary outcome measures (10)

• Safety : number and type of adverse reactions [Time frame: 3 months]
• Quality of life - PEmbQoL score [Time frame: 15 months]
• Pulmonary Vascular Obstruction index [Time frame: 3 months]
• Incidence of dyspnea [Time frame: 3 months and 15 months]
• Change of 6 Minutes Walk Test [Time frame: 3 months and 15 months]
• Change of Psychological status [Time frame: 3 months and 15 months]
• Symptomatic recurrent PE [Time frame: 15 months]
• Arterial thromboembolic events [Time frame: 15 months]
• Deaths of all causes [Time frame: 15 months]
• Hospitalizations and acute medical events [Time frame: 15 months]

Eligibility criteria

Inclusion criteria

• Age ≥ 18 years
• Patient treated with at least 3 months and up to 8 months of anticoagulation for symptomatic EP diagnosed according the ESC and ACCP guidelines.
• Patients who have a PembQol score ≥ 10% and whose total scores for the subgroups Q7+8 (dyspnea) and Q4 (impact of daily life) are ≥ 10%.

Exclusion criteria

• Presence of CTEPH according to international guidelines
• Patients treated for acute PE with anticoagulants for more than 8 months
• Active cancer or in remission for less than two years
• Dyspnea post - COVID due to parenchymal injuries
• Post-COVID hyperventilation syndrome without pulmonary vascular perfusion sequelae.
• Physical or psychological inability to undertake PR
• Isolated or more distal segmental PE
• Neuro-muscular disease with PR contraindication.
• Cardiac insufficiency (unstable coronary artery disease)
• Severe respiratory failure (long-term oxygen therapy, pulmonary hypertension)
• Chronic dyspnea MMRC ≥ 2 before PE
• Cardiac or respiratory rehabilitation in the previous year
• Indication to urgent PR within 6 months at the time of inclusion
• Life expectancy of less than 12 months
• Inability to give consent
• Patient under guardianship or curatorship
• Patient deprived of liberty by an administrative or judicial decision
• Patient has not social security affiliation or who don't beneficiary of such social security

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Supportive care

Study locations

France · 6 centers

• CHU Brest — Brest
• CHU Angers — Angers
• CHU de Grenoble — Grenoble
• CHBS Lorient — Lorient
• Hegp (Ap-Hp) — Paris
• CHU Saint-Etienne — Saint-Etienne

Identifiers

NCT: NCT05015153 · 29BRC21.0093 (RAMBO)

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗